Analysts Offer Predictions for Aerovate Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:AVTE)

Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Rating) – Stock analysts at Wedbush dropped their Q2 2023 earnings estimates for shares of Aerovate Therapeutics in a note issued to investors on Wednesday, May 17th. Wedbush analyst A. Argyrides now anticipates that the company will post earnings per share of ($0.63) for the quarter, down from their […]

Related Keywords

United States ,Ralph Niven ,Timothyp Noyes ,Atlas Venture Life Science Advisors ,Nasdaq ,Aerovate Therapeutics Inc ,Jpmorgan Chase Co ,Great Point Partners ,Geode Capital Management ,Aerovate Therapeutics ,Get Rating ,Aerovate Therapeutic ,Capital Management ,Point Partners ,Venture Life Science Advisors ,Aerovate Therapeutics Daily ,Nasdaq Avte ,Navte ,Medical ,Earnings Estimates ,Wedbush ,